Abstract
Aim: In this study, we have invastigated the anti-myeloma effect of the combination of these two agents againts CD 20 antigen positive and negative multpile myeloma (MM) cell lines. Material and Method: ARH-77 and RPMI-8226 were cultured with rituximab and zoledronic acid singly or combination. After evaluation for proliferation inhibition CD20 measurements is made for ARH-77 cell line and RPMI-8226 cell line in efficient concentrations. Findings: We have found that these two agents had antagonistic activity againts both ARH-77 and RPMI-8226 cell lines. As an unexpected finding, complement alone exhibited prominent proliferative activity on RPMI -8226 cells. Conclusion: In MM and plasma celll leukemia in which there is potential for rituximab use, it is suggested that combination with zoledronic acid may not be a suitable approach.
Keywords: Multiple myeloma, CD20, Zoledronic acid, Rituximab, Complement
